Segment Information (Tables)

6 Months Ended

Jun. 30, 2026

Segment Reporting [Abstract]

Schedule of Reconciliation to Consolidated Operating Expenses

A reconciliation to consolidated operating expenses as the Company’s single segment operating loss for the three and six months ended June 30, 2026 and 2025 is included in the table below:


		Three Months Ended June 30,								Six Months Ended June 30,
		2026				2025				2026				2025
		(in thousands)								(in thousands)
Research and development expenses:
INHBE program		$	6,870			$	3,515			$	11,706			$	6,054
AATD program			2,989				1,846				4,739				3,292
DMD program			3,953				2,681				8,091				5,719
HD program			157				789				220				1,956
Other research and development expenses(1), including PNPLA3, additional preclinical programs, PRISM			37,324				34,638				73,977				67,070
Total research and development expenses			51,293				43,469				98,733				84,091
General and administrative expenses			24,781				17,989				46,884				36,346
Total operating expenses		$	76,074			$	61,458			$	145,617			$	120,437

(1) Includes expenses related to other research and development programs, identification of potential drug discovery candidates, compensation-related expenses, internal manufacturing expenses, equipment repairs and maintenance expense, facility-related expenses, and other operating expenses, which are not allocated to specific programs.